The Global Uveitis Treatment Market Continues To Grow Owing To the Increasing Prevalence of Uveitis in the World

 

Uveitis Treatment Market

Uveitis Treatment Market, by Treatment Type (Corticosteroids, Immunosuppressant, Monoclonal Antibodies, Cycloplegic Agents, Antibiotics, Antivirals, Antifungal, Analgesics), by Disease type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, Pan uveitis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030.

Market Overview:

Global Uveitis Treatment Market size is estimated to be valued at US$ 710.0 million in 2022 and is expected to exhibit a CAGR of 5.3% between 2022 and 2030.

Uveitis is an inflammatory condition that affects the uvea, which is the middle layer of the eye that contains blood vessels that supply the retina. The uvea also includes the iris (the colored part of the eye), the ciliary body (which produces the fluid inside the eye), and the choroid (which supplies blood to the retina).

Treatment for uveitis depends on the underlying cause and the severity of the inflammation. It may include the use of topical or oral corticosteroids to reduce inflammation, immunosuppressive drugs to prevent the immune system from attacking the eye, and biological agents that target specific components of the immune system. In severe cases, surgery may be necessary to treat complications such as cataracts or glaucoma that can develop as a result of uveitis.

Competitive Landscape:

Major players operating in the global Uveitis Treatment Market include Santen Pharmaceuticals, EyePoint Pharmaceuticals, Alimera Science Inc., Eyegate Pharmaceuticals, Inc., AbbVie Inc., Bausch Health Inc., Novartis AG, and AbbVie (Allergan), Inc.

Key Market Drivers:

Uveitis is a relatively common inflammatory condition of the eye that affects people of all ages. The increasing prevalence of uveitis, particularly in developing countries, is expected to drive the growth of the global Uveitis Treatment Market. For instance, according to the American Ocular Immunology and Uveitis Foundation, every year around 43,000 new cases of uveitis are diagnosed every year in the United States. Uveitis can cause vision loss and blindness if left untreated, leading to a higher demand for effective treatments.

Biologic drugs, which are derived from living cells and are designed to target specific components of the immune system, have emerged as an effective treatment option for uveitis. The growing demand for biologics is estimated to enhance the growth of the global uveitis treatment market.

Covid-19 Impact Analysis:

During the COVID-19 pandemic, there have been several developments in the global Uveitis Treatment Market. For instance, in December 2020, Alimera Sciences Europe Limited introduced ILUVIEN in the Netherlands.

Key Takeaways:

·       North America is expected to dominate the growth of the global uveitis treatment market. The region's growth is driven by the high prevalence of uveitis, the availability of advanced healthcare facilities, and the high adoption of biologics. For instance, in October 2021, Clearside Biomedical and Bausch + Lomb the United States Food and Drug Administration approved an injectable suspension called XIPERE.

·       The Asia-Pacific region is estimated to witness high growth in the global uveitis treatment market, due to the increasing prevalence of uveitis, the rising geriatric population, and the growing healthcare infrastructure in developing countries. For instance, according to AmbitionBox, there are around 175 biotechnology companies in India currently.